Plain-English translation of NCT07581184 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called [225Ac]Ac-AKY-2519, which is a type of targeted radiation therapy designed to treat metastatic castration-resistant prostate cancer — an advanced form of prostate cancer that has stopped responding to hormone treatments. The medication works by targeting cancer cells and delivering radiation directly to them. Researchers are testing different doses of this treatment to find the safest and most effective amount.
Many men with advanced prostate cancer eventually develop resistance to standard hormone therapies, leaving them with limited treatment options. This trial exists to see whether this new radiation-based treatment can help patients whose cancer has progressed despite other therapies.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication as an intravenous infusion at a hospital or cancer center. The trial has two separate groups: one for patients who have never received a similar radiation therapy before, and one for patients who have. Researchers will test increasing doses to find the safest effective amount, and you would be monitored closely with blood tests, imaging scans, and clinical visits to track how you respond and watch for any side effects.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States